Liquid Biopsy Predicts Immunotherapy Response in Breast Cancer and Refines Chemotherapy Decisions in Germ Cell Tumors
Two studies show liquid biopsy can predict immunotherapy response in HER2-negative breast cancer and identify which patients with relapsed germ cell tumors may benefit from high-dose chemotherapy, advancing precision oncology.